Boston Scientific Corporation $BSX Shares Sold by Credit Agricole S A

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Credit Agricole S A decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,805,720 shares of the medical equipment provider's stock after selling 177,135 shares during the quarter. Boston Scientific accounts for about 0.6% of Credit Agricole S A's holdings, making the stock its 25th biggest holding. Credit Agricole S A owned about 0.12% of Boston Scientific worth $182,161,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new position in shares of Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the first quarter valued at approximately $27,000. Finally, Ameriflex Group Inc. purchased a new position in shares of Boston Scientific in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Oppenheimer raised their price objective on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Leerink Partners began coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Finally, Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average price target of $117.50.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock valued at $35,976,603 in the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.7%

BSX stock traded up $0.7850 during midday trading on Friday, reaching $105.9950. 9,396,775 shares of the company were exchanged, compared to its average volume of 6,321,979. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1-year low of $78.53 and a 1-year high of $108.94. The stock's 50-day simple moving average is $104.10 and its 200 day simple moving average is $102.12. The company has a market cap of $157.06 billion, a price-to-earnings ratio of 63.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company earned $0.62 earnings per share. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.